Contact Us

AI-based, Personalized
Frequency Medicine

Reimagining Diabetes Management
with Extremely Low Frequency
Electromagnetic Fields (ELF-EMF) 

Let's Speak

The Problem: Most Diabetics Reject CGMs & Struggle to Manage their Diabetes

of T1D don’t use CGMs
(Continuous Glucose Monitor)
~ 90 %*
of T2D don’t use CGMs
(Continuous Glucose Monitor)​
~ 95 %*

Top Barriers Why Diabetics Reject CGMs*

Do not like having (invasive) diabetes devices on their body

Cost of device, supplies or insurance coverage

Too many (false) alarms

* Data from the American Diabetes Association: Standards of Medical Care in Diabetes–2022.

Novel Solution: World’s 1st ELF-EMF-based Non-invasive Theranostic Platform (SW & Hardware)

  • Cloud-based real-time proprietary diagnostic & therapeutic algorithms
  • Non-invasive wearable sensor + ELF-EMF* generator
  • Constant ELF-EMF sensing, generation, & feedback to normalize blood sugar levels

Hardware
Development

Software
Development

Pre-clinical &
Clinical Trials

Intellectual
Property

Wellness to
FDA Approval

*ELF-EMF are Extremely Low-Frequency Electromagnetic Fields 

Phase 1 Product Development
Glycemic Event Early-Warning Device

  • Wearable watch-like device to predict glycemic events & give ~20-30 minute general warning
  • Generalized warnings don't require FDA trials/approval
  • Early warnings complement the use of CGM systems

Product Phase 2*:
Non-Invasive Theranostic

  • Non-invasive wearable with minimal patient
    pro-activity needed
  • Closed-loop diagnostic & therapeutic
    subscriptions     for diabetes management
  • Focus on strategic partnerships, IP licensing,
    & collaborations for distribution

*Regulatory body approval required

The Challenge Today

Electromagnetic
field treatments are
DIAGNOSTIC DEPENDENT

BUT

There is no integrated hardware/software
solution to identify
WHEN & WHAT
frequency to give

Traction Highlights

Hardware:
TDK Collaboration

TDK offers new miniaturized Migne sensors for clinical testing

TDK interested in assisting Tedence to create a wearable ELF-EMF device

Currently undergoing preparation for upcoming clinical trials

Software:
Evolution.Inc Collaboration

  • Contracted with Evolution.Inc (AI for AI) to create next-gen algorithm to provide real-time analysis
  • Algorithm & IP 100% owned by Tedence
  • Unique frequency & waveform discovered using AI/ML genetic algorithms & natural selection
  • Hypo- & hyperglycemic warning at ~20-30 minutes

We’re Starting with
“Diabetes: A Defining Disease of the 21st Century”

The Lancet, June 2023

37 Million

~10% of US suffers from Diabetes

1 in 3

Americans born today will get Diabetes

$1 in $4

US healthcare dollars spent on diabetes

Preventing Hypoglycemia Improves
Healthcare Economics for Payers

  • Hypoglycemia is a serious complication of diabetes that can lead to hospitalization and other costly healthcare services
  • Annual cost of hypoglycemia-related healthcare services (in US) for people with T1D is $2.4 billion & $1.1 billion for T2D
  • Interventions to prevent hypoglycemia can save Payers money. One program that provided education & support to people with T1D to help them prevent hypoglycemia saved Payers +$1,000/patient/year

Join us!

Let's give our loved ones a healthy future without needing needles & drugs

M: +972.54.6644747

E: [email protected]

www.tedence.com